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A B S T R A C T
Pharmacologic therapy reduces cardiovascular risk in a variety of primary and secondary prevention clin-
ical situations in addition to lifestyle modiﬁcations. Low density lipoprotein cholesterol (LDL-C) is a key
mediator of atherogenesis. Most cholesterol guidelines propose speciﬁc LDL-C while recently the ACC/
AHA recommends statin therapy without a speciﬁc LDL-C target. Proprotein convertase subtilisin kexin
9 (PCSK9) is a serine protease that leads to LDL receptor degradation. The decreased availability of LDL
receptors results in decreased clearance and an increase of circulating LDL-C particles. Monoclonal an-
tibodies that inhibit PCSK9 (PCSK9 abs) reduce LDL-C levels and may be especially helpful in familial
hypercholesterolemia and statin-intolerant patients. PCSK9 inhibition is an exciting and promising new
therapy for protection against macrovascular events.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Abundant data indicate that, in addition to lifestyle modiﬁca-
tion, pharmacologic lipid-lowering therapy reduces cardiovascular
risk in a variety of primary and secondary prevention clinical situ-
ations. Though the majority of the randomized controlled trials
involve statins, there is some data supporting the eﬃcacy of niacin
and gemﬁbrozil in these situations [1].
Over the years there have been different recommendations regard-
ing treatment of dyslipidemia. Most of the guidelines have proposed
speciﬁc low density lipoprotein cholesterol (LDL-C) targets [2–4]. Re-
cently, the American College of Cardiology/AmericanHeart Association
(ACC/AHA) recommended the use of speciﬁc statins for treatment of
dyslipidemia without aiming for a speciﬁc LDL-C target [1].
While the ACC/AHA did not target a certain LDL-C level, we do not
think that this was meant to imply that LDL-C was not important or
not atherogenic, just that themany studies showing statin beneﬁt did
not show the beneﬁt of statin titration to a certain LDL-C level.
Indeed, there is an excellent physiologic basis for believing that
LDL-C is very atherogenic and, logically, that lowering LDL-C asmuch
as possible would have incremental beneﬁt. The major carrier of
cholesterol in most humans is LDL-C. LDL-C particles are variable
in size and contain a hydrophobic cholesterol core lined by a phos-
pholipid coat containing the lipoprotein apolipoprotein B (apoB).
Atherosclerotic plaque starts with LDL-C inﬁltration into arterial walls
where LDL-C is able to bind to glycosaminoglycans followed by oxi-
dative processes which lead to a modiﬁed apoB recognized and
internalized by receptor-mediated macrophage endocytosis. These
macrophages transform into cholesterol-laden foam cells that secrete
cytokines leading to inﬂammation, smoothmuscle proliferation, and
plaque formation within the arterial wall [5]. A ﬁbrous cap forms
a barrier between prothrombotic material on the surface of the
plaque and platelets which can facilitate thrombus formation [6].
Atherothrombosis can lead to arterial occlusion and end organ
damage.
Most cells express the LDL-C receptor which recognizes the apoB
portion of LDL-C and mediates LDL-C clearance from the circula-
tion [7]. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine
protease produced predominantly in the liver that leads to the deg-
radation of hepatocyte LDL-C receptors and subsequently to increased
circulating LDL-C levels. It circulates in three forms: a PCSK9
monomer, LDL-C-bound PCSK9, and a 55 kDa furin-cleaved inac-
tive fragment [8]. The transcription factor sterol regulatory element–
binding protein 2 (SREBP2) regulates LDL-C receptor expression and
increases PCSK9 synthesis. PCSK9 binds to an epidermal growth
factor (EGF)–like repeat located at the extracellular domain of the
LDL-C receptor and is subsequently internalized and prevents the
recycling of LDL-C receptors to the cell surface. As displayed in
Figure 1, the resultant decrease in the number of LDL-C receptors
by means of lysosomal degradation leads to an increase of LDL-C
particles in circulation which contributes to the generation of ath-
erosclerotic plaque. Sequence variations that cause decreased activity
of the PCSK9 gene leading to decreased serum LDL-C is associated
with coronary heart disease risk reduction [9].
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Therapies that lower circulating PCSK9 levels signiﬁcantly lower
LDL-C levels. This category of lipid lowering therapy offers an
important option not previously available and has demonstrated
signiﬁcant eﬃcacy in lowering LDL-C and a large meta-analysis
has suggested that this lowering might decrease adverse CV
outcomes. Monoclonal antibodies that inhibit PCSK9 (anti-PCSK9
abs) reduce LDL-C by as much as 70% in a dose dependent
manner. They have been shown to lower LDL-C by as much as 60%
in statin treated patients [10]. A comprehensive meta-analysis of
24 randomized trials (n = 10,159) encompassing a large cohort
of clinical situations including familial hypercholesterolemia,
statin-intolerant patients, and those not on any statin therapy
found that anti-PCSK9 abs lowered all-cause mortality (odds ratio
[OR] 0.45, 95% CI 0.23–0.86), CV mortality (OR 0.50, CI 0.23–1.10),
and MI (OR 0.49, CI 0.26–0.93) [11]. The beneﬁts of anti-PCSK9
abs appear to be similar across a wide range of clinical situations
and CV risks similar to what has been noted with statin therapy.
Therapy with anti-PCSK9 abs appears to result in additional reduc-
tions in CV risk even in patients already on intensive or maximal
statin therapy. Table 1 displays similarities and differences between
the current FDA approved PCSK9 inhibitors in select placebo
controlled trials.
Figure 1. PCSK9 plays an important role in regulating the number of LDL-C receptors located at the hepatocyte cell surface. In the absence of PCSK9, the LDL particle binds
to the LDL receptor followed by internalization. The LDL particle is targeted for degradation by the lysosome and the LDL receptor is recycled to the cell surface. In the
presence of PCSK9, PCSK9 binds to the LDL particle-LDL receptor complex. The LDL receptor bound to PCSK9 is unable to recycle to the cell surface and is subject to deg-
radation. A decrease in LDL receptors results in an increase of serum LDL particles.
Table 1
Comparison of the FDA-approved PCSK9 Inhibitors
Alirocumab Evolocumab
Monoclonal Ab Characteristics 100% Human
4th generation
IgG1
100% Human
4th gen
IgG2
Indications for Use HeFH HoFH, HeFH
LDL-C Reduction
Trial Odyssey Long-Term Mendel-2
Duration 24 weeks 12 weeks
Biweekly Therapy Alirocumab Placebo Evolocumab Placebo
Percentage (%) −61.0 0.8 −57.0 0.1
Dosage and Administration 1. Injection: 140 mg/mL solution in a single-use preﬁlled syringe
2. Injection: 140 mg/mL solution in a single-use preﬁlled SureClick® autoinjector
To administer the 420 mg dose, give three 140 mg/dL injections consecutively
within 30 minutes
1. Injection: Single-dose pre-ﬁlled pen/syringe
75 mg/mL
150 mg/mL
Cost ~ $15,000/year ~$14,500/year
Adverse Effects Nasopharyngitis, Bronchitis, Sinusitis, Inﬂuenza, Cough, Myalgia, Urinary tract infections, Diarrhea, Muscle spasms, Musculoskeletal
pain, Injection site reactions, Neurocognitive effects
HeFH = Heterozygous Familial Hypercholesterolemia; HoFH = Homozygous Familial Hypercholesterolemia.
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Alirocumab trials
Alirocumab (Praluent) is a human monoclonal antibody against
PCSK9. In the Eﬃcacy and Safety of Alirocumab SAR236553
(REGN727) Versus Ezetimibe in Patients with Hypercholesterol-
emia (ODYSSEY MONO) study, alirocumab was evaluated in 103
patients with hypercholesterolemia who were not on lipid-lowering
therapy but who had a 1–5% 10-year risk of CV death as assessed
by the European Systematic Coronary Risk Estimation. The pa-
tients were randomized to ezetimibe 10 mg daily or alirocumab
75mg every 2weeks. The alirocumab dose was titrated up to 150mg
if week 8 LDL-C was ≥70mg/dL. After 24 weeks, alirocumab reduced
LDL-C by 47% compared with 16% with ezetimibe. With alirocumab,
levels of apo B and non–HDL-C were reduced by 37% and 41%, re-
spectively. There were no differences in treatment-related adverse
events between alirocumab and ezetimibe [12].
In the Study of Alirocumab (REGN727/SAR236553) in Patients
with Primary Hypercholesterolemia and Moderate, High, or Very
High Cardiovascular Risk who are Intolerant to Statins (ODYSSEY
ALTERNATIVE) trial, alirocumabwas evaluated in patients with statin
intolerance who did not have muscle-related adverse events on
screening with subcutaneous or oral placebo. Patients (n = 314) were
randomized to alirocumab 75 mg every 2 weeks, ezetimibe 10 mg
daily, or atorvastatin 20 mg daily. At 24 weeks of treatment,
alirocumab reduced LDL-C by 45% compared with 15% with
ezetimibe. Treatment-emergent adverse events were similar in the
2 groups, with rates of skeletal muscle-related events being lower
in the alirocumab than in the atorvastatin group [13,14].
The Eﬃcacy and Safety of Alirocumab (SAR236553/REGN727)
Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Pa-
tients with Hypercholesterolemia (ODYSSEY COMBO) I and II trials
tested alirocumab as add-on therapy to maximally tolerated statin
in high-CV disease-risk patients with suboptimal cholesterol control.
In ODYSSEY COMBO I, patients (n = 316) were randomized to 75mg
every 2 weeks or placebo. After 24 weeks, alirocumab reduced LDL-C
by 48% compared with 2% with placebo [15].
In Eﬃcacy and Safety of Alirocumab (SAR236553/REGN727)
Versus Ezetimibe on Top of Statin in High Cardiovascular Risk
Patients with Hypercholesterolemia (ODYSSEY COMBO II), pa-
tients (n = 720) were randomized to 75 mg every 2 weeks or
ezetimibe 10 mg daily. After 24 weeks, alirocumab reduced LDL-C
by 51% compared with 21% with ezetimibe [16].
The Long-term Safety and Tolerability of Alirocumab (SAR236553/
REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High
Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY
LONG-TERM) trial evaluated the eﬃcacy and safety of treatment with
alirocumab for 78 weeks in patients with heterozygous familial hy-
percholesterolemia with established CHD or CHD equivalent with
LDL-C ≥70 mg/dL on maximal tolerated statin dose (47% of pa-
tients were on high-dose statin) or other lipid-lowering therapy.
Patients (n = 2341) were randomized to alirocumab 150 mg or
placebo every 2 weeks. Alirocumab decreased LDL-C by 61% from
baseline at 24 weeks and by 52% at 78 weeks. Reductions in non–
HDL-C of 52%, apo B of 54%, and Lp (a) of 26% were observed with
alirocumab therapy. In addition to evaluating safety and eﬃcacy,
the trial collected data on prespeciﬁed adjudicated CV disease out-
comes. Notably, a post hoc analysis showed that treatment with
alirocumab was associated with a lower rate of major adverse car-
diovascular outcomes [17].
In addition to the already completed safety and eﬃcacy trials,
there is a large ongoing outcome trial evaluating the impact of PCSK9
inhibition with alirocumab on CVD end points. The ODYSSEY Out-
comes: Evaluation of Cardiovascular Outcomes After an Acute
Coronary Syndrome During Treatment with Alirocumab SAR236553
(REGN727; ODYSSEY OUTCOMES) trial will randomize 18,000
patients to alirocumab every 2 weeks or placebo who have had
recent hospitalization for acute myocardial infarction or unstable
angina and are on a background of statin therapy. The primary
outcome is time to ﬁrst occurrence of CHD death, acute myocar-
dial infarction, hospitalization for unstable angina, or ischemic stroke.
The estimated study completion date is January 2018 [18].
Evolucumab trials
Evolucumab (Repatha) is another human monoclonal antibody
against PCSK9. The MENDEL studies in 2012 and 2014 proved the
signiﬁcant reduction in LDL-C by 55–57% from baseline compared
to placebo and 38–40% more than ezetimibe with both biweekly
and monthly doses of Evolucumab [19,20]. Signiﬁcant increase in
HDL-C and decrease in triglycerides and VLDL-C levels was also ob-
served. Three hundred seven patients intolerant to at least 2 statins
were randomized in the GAUSS-2 placebo and ezetimibe con-
trolled study [21]. Similar reduction in LDL-C was noted (55–56%).
More than 75% achieved LDL-C less than 100 mg/dL in 12 weeks.
The drug was well tolerated with very low incidence of myalgia, 7%
and 9% in the weekly and monthly doses respectively.
Patients with primary hypercholesterolemia and mixed
dyslipidemia on moderate or high intensity statins, when given a
trial of evolocumab either biweekly or monthly, showed equal re-
ductions in LDL-C by 65–75% over a 12-week trial, compared to
placebo (LAPLACE-2) [22]. The reduction in LDL-C observed was sig-
niﬁcantly greater (66%) with evolocumab when compared to
ezetimibe (24%). About 86–94% of patients achieved LDL-C <70mg/dL
in 12weeks with evolocumab and background statin therapy, in con-
trast to 17–62% achieving the same goal in the ezetimibe group.
Subsequent to 12 weeks, analysis of effects on other lipids dem-
onstrated 12% and 6–16% reduction in the triglycerides with the
biweekly and monthly doses respectively. HDL-C levels were mod-
estly elevated by 5–10% in both dose groups. Evolocumab was well
tolerated, with an uncommon incidence of neurocognitive events
≤1% in this study.
In January 2015, Lancet published the TESLA Part B (a random-
ized, double-blinded, placebo controlled, phase 3 trial) [23] conducted
at 17 sites in 10 countries (North America, Europe, the Middle East,
and South Africa) on 50 patients with homozygous familial hyper-
cholesterolemia (HoFH) ≥12 years of age. After 4 weeks of a stable
lipid lowering agent (statin with or without ezetimibe) without re-
ceiving apheresis, patients randomized to the evolocumab group
(420mg subcutaneous monthly) signiﬁcantly reduced the LDL-C at
12 weeks by 30.9% compared to placebo. Upper respiratory tract in-
fections and inﬂuenza were the most common adverse events noted
in the evolocumab group with no serious adverse events noted.
The RUTHERFORD-2, a multicenter randomized 12 week study
of 331 participants with heterozygous familial hypercholesterol-
emia (HeFH) age 18–80 years showed a robust 60% reduction in
LDL-C compared to placebo [24]. Nasopharyngitis and muscle-
related adverse events were the most commonly reported side
effects.
The year 2015 also introduced the OSLER studies: OSLER 1 (com-
prising of patients completing phase 2 trials in 190 centers) and
OSLER 2 (comprising of patients completing phase 3 trials in 305
centers); 2 open labeled randomized trials with more than 4000
patients, studied the eﬃcacy and safety of evolocumab in reduc-
ing lipids and cardiovascular events [25]. Evolocumab reduced
cholesterol levels by 61% in 12 weeks compared to the standard
therapy alone, by reducing the pretreatment median of 120 mg/
dL to 48 mg/dL and, sustaining the reduction through 48 weeks.
Evolocumab was reported to have nonspeciﬁc adverse events (ar-
thralgia, headache, limb pain, and fatigue) and some neurocognitive
adverse events like dementia, delirium, confusion, amnesia, attention
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deﬁcits, disturbance in mental thinking and perception, more fre-
quently than the standard therapy group. The cardiovascular beneﬁts
are yet to be established. Though the analysis was exploratory, the
modest reduction in LDL-C showed consistency with the one-year
reduction in cardiovascular events in the OSLER trials. However, larger
randomized placebo controlled trials are underway with the in-
tention of providing a more conclusive assessment of the
cardiovascular beneﬁt of evolocumab [Further Cardiovascular Out-
comes Research with PCSK9 Inhibition in Subjects with Elevated Risk
(FOURIER) study] [26].
Evolocumab is indicated as an adjunct to diet andmaximally tol-
erated statin therapy for the treatment of adults with HeFH or clinical
atherosclerotic CV disease and HoFH in conjunction with diet and
other lipid-lowering therapies (e.g. statins, ezetimibe, LDL-C
apheresis), who require additional lowering of LDL-C. Two dose for-
mulations are available, 140 mg subcutaneous every 2 weeks or
420 mg monthly. Nasopharyngitis, upper respiratory tract infec-
tions, injection site reactions, myalgias, headaches and, rarely,
neurocognitive effects were among the noted adverse effects.
The role of PCSK9 and statin in lowering LDL-C is additive, 70%
when combined as compared to 50% when used alone, with
maximum lowering effect seen within 2 weeks of therapy [27].
Summary
PCSK9 inhibition is an exciting and promising new therapy for
protection against macrovascular events. However, for now, use
should be restricted to those with familial hypercholesterolemia or
patients with clinical atherosclerotic cardiovascular disease, who
require additional lowering of LDL-C. Prospective trials examining
CV outcomes are underway and the results are eagerly awaited.
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